Key statistics
As of last trade, Vanda Pharmaceuticals Inc (VNDA:NMQ) traded at 6.04, 58.56% above the 52 week low of 3.81 set on May 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.06 |
|---|---|
| High | 6.28 |
| Low | 6.02 |
| Bid | 6.04 |
| Offer | 6.05 |
| Previous close | 6.09 |
| Average volume | 1.40m |
|---|---|
| Shares outstanding | 59.11m |
| Free float | 53.39m |
| P/E (TTM) | -- |
| Market cap | 359.97m USD |
| EPS (TTM) | -3.74 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 18:21 GMT.
More ▼
- Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
- Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
- Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
- Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
- Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
- Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
- FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
- Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
More ▼
